Keeping Track: Intercept Submits OCA For NASH; Zogenix’ Fintepla Returns; US FDA Approves Bavarian Nordic Vaccine
Executive Summary
The latest drug development news and highlights from our US FDA Performance Tracker
You may also be interested in...
Monkeypox: Bavarian Nordic’s Jynneos Vaccine Should Be Given Only As A Two-Dose Series, US FDA Says
Despite limited vaccine supplies and a growing number of cases, public health officials nix the idea of giving only one dose of Jynneos to individuals exposed or at high risk, saying that two doses one month apart are required for full protection; FDA says it is working to expedite the availability by late July of an additional 786,000 doses made in Denmark.
Keeping Track: Two Novel Migraine Drugs Highlight Busy Week For US FDA Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
Zogenix’s Fintepla Reduces Drop Seizure Rates, But Is It Enough?
Despite positive Phase III results in Lennox-Gastaut syndrome, the effect of the company’s low-dose fenfluramine on serious seizures may not be as good as seen with GW Pharma’s Epidiolex.